# RECIST 1.1 Implementation: 2024-2025 Research Context

## Current Standards Implementation

This repository implements **RECIST 1.1** (Eisenhauer 2009) following:
- CDISC SDTM IG v3.4 (TU/TR/RS domains)
- CDISC ADaM IG v1.3 (BDS structure)
- CDISC ADRECIST v1.0 (September 2024) [web:25]

## Contemporary Research Developments

### AI-Assisted Measurement (2024)
**Status**: Foundation models demonstrate 34.5% improvement in measurement accuracy[web:27]

**Implementation Gap**: This repository uses manual SDTM data input; AI integration would require:
- DICOM image server integration
- Commercial AI platform licensing (RSIP Vision, Intrasense Liflow, etc.)
- FDA validation path (evolving regulatory framework)

**Estimated Integration Effort**: 60-80 hours + licensing costs

### Simplified Thresholds: 25mm Nadir Rule (Enaworu 2025)
**Proposal**: Replace dual threshold (20% + 5mm) with single absolute: Nadir + 25mm

**Validation**: Complete concordance in 1,000-patient study (255/255 PD classifications matched)[web:23]

**Repository Impact**: Could add optional parameter to existing macros:
```
%derive_target_lesion_response(
    /* ... existing parameters ... */
    pd_threshold_type=STANDARD,  /* or SIMPLIFIED */
    pd_simplified_mm=25
);
```

**Implementation Effort**: 4-6 hours (macro modification + validation testing)

### iRECIST Validation Status (2024)
**Evidence Base**: Meta-analyses show advantage **only for anti-CTLA-4 antibodies**; no significant difference for PD-1/PD-L1 inhibitors[web:27][web:51]

**Repository Status**: 
- ✅ iRECIST macros code-complete in `immunotherapy/` directory
- ❌ Not validated with test data
- ⚠️ Requires tumor type-specific clinical consultation

**Recommendation**: Mark as "experimental" until prospective validation published

### Radiologists' Wishlist (UCLA November 2024)[web:15]

**Key Proposals**:
1. Increase target lesions from 5 to 10 (reduce selection bias)
2. Quantify non-target with +100% doubling threshold (vs. subjective "unequivocal")
3. Require new lesions ≥10mm OR growth on confirmatory scan

**Repository Alignment**:
- Current implementation: Standard RECIST 1.1 (5 lesions, qualitative non-target)
- Future enhancement: Could parameterize lesion limits in macros

### Liquid Biopsy Integration (ctDNA-RECIST)

**Proposed Framework** (Gouda 2024)[web:27]:
- Collection timepoints: weeks 2, 4, 8 post-treatment
- Response criteria: non-overlapping confidence intervals

**Implementation Barrier**: Requires custom SDTM domains (LB, GE) not in standard oncology trials

**Estimated Effort**: 40-50 hours for SDTM mapping + ADaM derivation

## What This Repository Implements vs. Aspirational

| Feature | Status | Notes |
|---------|--------|-------|
| RECIST 1.1 core logic | ✅ Implemented | Validated with 3 test subjects |
| CDISC ADRECIST structure | ✅ Implemented | Per September 2024 guidance |
| Confirmation windows | ✅ Implemented | 28-84 days for CR/PR |
| iRECIST pseudoprogression | ⚠️ Code-complete | Not validated; tumor-specific |
| AI-assisted measurement | ❌ Not implemented | Requires DICOM integration |
| 25mm nadir simplification | ❌ Not implemented | 4-6 hour enhancement |
| ctDNA integration | ❌ Not implemented | Non-standard SDTM domains |
| Non-target quantification | ❌ Not implemented | Still uses qualitative "unequivocal" |

## References

1. CDISC ADRECIST v1.0 Presentation (China Interchange, August 2024)
2. Enaworu. "The 25mm Nadir Rule." Cureus, April 2025
3. Gouda et al. "Tumor therapeutics in the era of RECIST." Frontiers in Oncology, October 2024
4. UCLA Radiologists. "A call for objectivity in RECIST 1.1." PMC, November 2024
5. Nature Communications. "Towards evidence-based response criteria for immunotherapy." May 2023
